Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.63 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.63 |
| ▸ | HTR3B | O95264 | 3/20 | 0.63 |
| ▸ | HTR3A | P46098 | 3/20 | 0.63 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.63 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28708983 | 0.98 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL12832086 | 0.98 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6151182 | 0.98 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6151619 | 0.98 | ADRB1 (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL3236795 | 0.98 | ALDH1A1 (0.63) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL6152907 | 0.96 | MAPT (0.61) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2319970 | 0.92 | ALDH1A1 (0.62) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL3214287 | 0.90 | ALDH1A1 (0.66) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5570604 | 0.88 | ADRB1 (0.77) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14889015 | 0.87 | MAPT (0.50) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136781-A | ROR 1-targeted inhibitor and synthesis method and application thereof | 北京大学 | 2025-06-13 | — | — | CN | claimed |
| CN-115108931-B | Tofenamic acid derivative and preparation and application thereof | 南华大学附属第一医院 | 2024-06-14 | — | — | CN | claimed |
| CN-118085890-A | Liquid crystal aligning agent and preparation method and application thereof | 合肥中聚和成电子材料有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-116178880-B | Preparation method of intumescent flame retardant modified ABS resin | 揭阳市万润新材料有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117866199-B | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element thereof | 烟台三月科技有限责任公司 | 2024-05-28 | — | — | CN | claimed |
| CN-117866199-A | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display element thereof | 烟台三月科技有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117777003-A | 4-piperazinyl anilino and 2-piperazinyl propionamido derivatives and application thereof in preparation of anti-pulmonary fibrosis drugs | 清远中大创新药物研究中心 | 2024-03-29 | — | — | CN | claimed |
| CN-116814278-A | Liquid crystal aligning agent, liquid crystal alignment film prepared by using the same and display element containing the alignment film | 合肥中聚和成电子材料有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116178880-A | Preparation method of intumescent flame retardant modified ABS resin | 揭阳市万润新材料有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-113045755-B | Alignment film material, liquid crystal alignment agent, liquid crystal alignment film, and liquid crystal display element | 深圳清荷科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-1809381-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | Recepticon ApS (DK) | 2007-07-25 | — | — | EP | claimed |
| EP-1781647-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2007-05-09 | — | — | EP | claimed |
| US-20070004727-A1 | Use of compounds for the prevention of drug-induced cell toxicity | RECEPTION APS C/O OSTYSK INNOVATION A/S (DK) | 2007-01-04 | — | — | US | claimed |
| WO-2006037335-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | RECEPTICON APS (DK) | 2006-04-13 | — | — | WO | claimed |
| WO-2006008545-A2 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-26 | — | — | WO | claimed |
| EP-1610773-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | Recepticon ApS (DK) | 2006-01-04 | — | — | EP | claimed |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | US | claimed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | claimed |
| WO-2004084876-A2 | USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY | RECEPTICON APS (DK) | 2004-10-07 | — | — | WO | claimed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004727-A1 | Use of compounds for the prevention of drug-induced cell toxicity | SLC10A6, SLC47A1, SLC47A2 | ADRB1 1450/4885HTR3E 1108/4885HTR3B 1028/4885 |
| US-20050182050-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | ADRB1 69/4885HTR3E 19/4885HTR3B 4/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | ADRB1 61/4885HTR3E 18/4885HTR3B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.